Ambrosia Biosciences

Stub active Updated Apr 3, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location Boulder, Colorado
Founded 2023
Latest Stage Series B
Total Raised $100M+
Website https://ambrosiabiosciences.com
Sector
biotech pharmaceuticals health-tech

About

Ambrosia Biosciences is a Boulder, Colorado-based drug discovery company developing orally delivered, small molecule-based therapies for obesity and other cardiometabolic disorders 1. The company’s lead program is an oral small molecule GLP-1 receptor agonist, positioning it to compete in the growing obesity therapeutics market beyond current peptide-based treatments 2.

Funding History

Date Round Amount Lead Co-investors
2026-03-31 Series B $100M Blue Owl Healthcare Opportunities, Redmile, Deep Track Capital BVF Partners, Boulder Ventures, Janus Henderson Investors, Samsara BioCapital 12

The round was oversubscribed 1.

What Investors Say

No verified investor quotes available at this time.

What Founders Say

No verified founder quotes available at this time.

Sources

  1. PR Newswire / Ambrosia Biosciences, “Ambrosia Biosciences Announces $100 Million Oversubscribed Series B Financing to Advance Novel Small Molecule Cardiometabolic Pipeline,” March 31, 2026. https://www.prnewswire.com/news-releases/ambrosia-biosciences-announces-100-million-oversubscribed-series-b-financing-to-advance-novel-small-molecule-cardiometabolic-pipeline-302729104.html↩↩↩

  2. Fierce Biotech, “Obesity biotech Ambrosia scores $100M series B to take next-gen oral GLP-1 into the clinic,” March 31, 2026. https://www.fiercebiotech.com/biotech/ambrosia-scores-100m-series-b-support-next-gen-glp-↩↩